XML 70 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Oct. 12, 2018
USD ($)
Feb. 28, 2019
USD ($)
Jul. 31, 2016
USD ($)
Nov. 30, 2016
USD ($)
Mar. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Segment
Dec. 31, 2017
USD ($)
Significant Accounting Policies [Line Items]                  
Accumulated deficit               $ (450,565,000) $ (374,232,000)
Working capital               56,100,000  
Cash and cash equivalents               56,992,000 81,146,000
Proceeds from issuance of common stock in follow-on offering, net of issuance costs       $ 59,100,000       $ 52,000 2,968,000
Decreased in investing activities         $ 1,500,000 $ 1,900,000 $ 1,900,000    
Increased in financing activities         $ 1,500,000 $ 1,900,000 $ 1,900,000    
Number of operating segment | Segment               1  
Cash and cash equivalents, restricted cash maturity period               Three months or less  
Impairments of long-lived assets               $ 0 0
Estimated useful life of intangible assets               2 years 6 months  
Revenue from product development award               $ 1,371,000 40,000,000
Reclassification of Restricted Cash to Cash and Cash Equivalents [Member] | ASU-2016-18 [Member]                  
Significant Accounting Policies [Line Items]                  
Reclassification of restricted cash               2,400,000  
Cancer Prevention & Research Institute of Texas [Member]                  
Significant Accounting Policies [Line Items]                  
Revenue from product development award     $ 20,000,000            
Teijin Limited [Member]                  
Significant Accounting Policies [Line Items]                  
Contract revenues received                 $ 40,000,000
Grant Revenue [Member]                  
Significant Accounting Policies [Line Items]                  
Revenue from product development award               1,371,000  
Grant Revenue [Member] | Cancer Prevention & Research Institute of Texas [Member] | Aravive Biologics [Member]                  
Significant Accounting Policies [Line Items]                  
Revenue from product development award $ 15,400,000                
Deferred Revenue               $ 100,000  
Grant Revenue [Member] | Cancer Prevention & Research Institute of Texas [Member] | Aravive Biologics [Member] | Subsequent Event [Member]                  
Significant Accounting Policies [Line Items]                  
Revenue from product development award   $ 2,600,000              
Assembled Workforce [Member]                  
Significant Accounting Policies [Line Items]                  
Estimated useful life of intangible assets               3 years  
Minimum [Member]                  
Significant Accounting Policies [Line Items]                  
Property and equipment estimated useful lives               3 years  
Maximum [Member]                  
Significant Accounting Policies [Line Items]                  
Property and equipment estimated useful lives               5 years  
Percentage for the amount of benefit realized upon ultimate settlement               50.00%